Viscaria A-zone drillings: VDD0203 returns 20m @1.27% Cu, including 5m @2.99% Cu. VDD0204 returns 18m @1.18% Cu, including 3m @3.28% Cu. Significant potential for cobalt and gold.
November 01, 2019 07:55 ET
|
Copperstone Resources AB
Kiruna November 1, 2019 VDD0203 intersected significant Copper and Gold mineralisation VDD0204 intersected significant Copper and Cobalt mineralisation VDD0205 visually appears to have...
Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
May 28, 2019 08:00 ET
|
Catalyst Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst...
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
May 02, 2019 08:00 ET
|
Catalyst Biosciences, Inc.
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation received from the European...
Severe Acute Respiratory Syndrome (SARS) Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, & Current Status of Pipeline Drugs
February 27, 2019 03:38 ET
|
Research and Markets
Dublin, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The "Severe Acute Respiratory Syndrome (SARS) Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status...
Cholera Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs
February 27, 2019 03:31 ET
|
Research and Markets
Dublin, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The "Cholera Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Cholera" ...
Equine Encephalitis Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs
February 27, 2019 03:25 ET
|
Research and Markets
Dublin, Feb. 27, 2019 (GLOBE NEWSWIRE) -- The "Equine Encephalitis Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for...
Influenza A Virus H7N9 Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs
February 26, 2019 11:36 ET
|
Research and Markets
Dublin, Feb. 26, 2019 (GLOBE NEWSWIRE) -- The "Influenza A Virus H7N9 Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs...
Shingles Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Shingles
February 04, 2019 04:58 ET
|
Research and Markets
Dublin, Feb. 04, 2019 (GLOBE NEWSWIRE) -- The "Shingles Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Shingles" ...
Melioidosis R&D Pipeline Analysis Report, H2-2018
January 28, 2019 11:40 ET
|
Research and Markets
Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Melioidosis R&D Pipeline Analysis Report, H2-2018" drug pipelines has been added to ResearchAndMarkets.com's offering. ...
Rhinovirus Infection Drug Pipeline Study, H2 2018 - Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs
January 28, 2019 11:35 ET
|
Research and Markets
Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Rhinovirus Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for...